Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL)

NCT01108341 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Hodgkin's Lymphoma (NHL)

Interventions

DRUG: Bendamustine hydrochloride
DRUG: Ofatumumab

Sponsor

Cephalon